Satoshi Mori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Satoshi Mori has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Soen
Soen Orthopaedics, Osteoporosis and Rheumatology Clinic, Kobe, Japan
5 shared publications Hiroshi Hagino
Department of Rehabilitation, Sanin Rosai Hospital, Yonago, Japan
4 shared publications- Hiroshi Hagino
Department of Rehabilitation, Sanin Rosai Hospital, Yonago, Japan
4 shared publications - Shiro Tanaka
Center for Clinical and Translational Research. Kyushu University Hospital, Fukuoka, Japan, f-labs 209 room. 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
4 shared publications - Teruki Sone
Department of Nuclear Medicine, Kawasaki Medical School, Okayama, Japan
4 shared publications Satoshi Soen
Osteoporosis and Rheumatology Clinic, Soen Orthopaedics, Kobe, Japan
3 shared publications
Latest Publications
- Open Access
- 13 February 2026
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 44 (3) , 454
Correction: Time-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis
- 13 February 2026
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 44 (3) , 454
Open AccessCorrection: Time-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis
- Open Access
- 31 July 2025
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 43 (5) , 546-552
Time-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis
Introduction: The effects of teriparatide (TPTD) and alendronate (ALN) on health-related quality of life (HRQOL) were evaluated in osteoporotic patients with high fracture risk using data from the JOINT-05 trial. Materials and methods: JOINT-05 was a randomized, controlled trial comparing the fracture prevention effects of sequential therapy with TPTD for 72 weeks followed by ALN for 48 weeks with those of ALN monotherapy for 120 weeks. This sub-analysis evaluated the effects of TPTD and ALN on HRQOL using data from baseline to 72 weeks. HRQOL was assessed at baseline, 4, 12, 24, 48, and 72 weeks using the EuroQoL-5Dimension (EQ-5D) questionnaire containing five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Scores were also transformed using utility weights derived from the general Japanese population. Results: This sub-analysis included 476 patients in the TPTD group and 492 patients in the ALN group. No significant differences in utility scores were observed between groups at all times. Utility scores improved significantly after 12 weeks in the TPTD group and after 24 weeks in the ALN group. Mobility and self-care scores improved significantly in the TPTD group. Significant improvements in usual activity, pain/discomfort, and anxiety/depression scores occurred earlier in the TPTD group. Conclusion: Although there were no significant differences in utility scores between the TPTD and ALN groups, significant improvements in the utility score and 5 domain scores were observed earlier in the TPTD group. When treating osteoporosis patients with a high risk of fracture, the selecting treatment drugs may be decided with primary consideration of its effect on fracture prevention, followed by its effect on improving HRQOL.
- 31 July 2025
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 43 (5) , 546-552
Open AccessTime-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis
Introduction: The effects of teriparatide (TPTD) and alendronate (ALN) on health-related quality of life (HRQOL) were evaluated in osteoporotic patients with high fracture risk using data from the JOINT-05 trial. Materials and methods: JOINT-05 was a randomized, controlled trial comparing the fracture prevention effects of sequential therapy with TPTD for 72 weeks followed by ALN for 48 weeks with those of ALN monotherapy for 120 weeks. This sub-analysis evaluated the effects of TPTD and ALN on HRQOL using data from baseline to 72 weeks. HRQOL was assessed at baseline, 4, 12, 24, 48, and 72 weeks using the EuroQoL-5Dimension (EQ-5D) questionnaire containing five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Scores were also transformed using utility weights derived from the general Japanese population. Results: This sub-analysis included 476 patients in the TPTD group and 492 patients in the ALN group. No significant differences in utility scores were observed between groups at all times. Utility scores improved significantly after 12 weeks in the TPTD group and after 24 weeks in the ALN group. Mobility and self-care scores improved significantly in the TPTD group. Significant improvements in usual activity, pain/discomfort, and anxiety/depression scores occurred earlier in the TPTD group. Conclusion: Although there were no significant differences in utility scores between the TPTD and ALN groups, significant improvements in the utility score and 5 domain scores were observed earlier in the TPTD group. When treating osteoporosis patients with a high risk of fracture, the selecting treatment drugs may be decided with primary consideration of its effect on fracture prevention, followed by its effect on improving HRQOL.
- 1 January 2025
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 43 (1) , 22-25
Sequential therapy following teriparatide treatment in patients at high risk of osteoporotic patients
The use of medications in sequence is recommended in several osteoporosis guidelines to afford the best protection for the patient at very high risk of fracture. Sequential therapy following once-weekly as well as daily teriparatide treatment is a potent option for those patients.
- 1 January 2025
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 43 (1) , 22-25
Sequential therapy following teriparatide treatment in patients at high risk of osteoporotic patients
The use of medications in sequence is recommended in several osteoporosis guidelines to afford the best protection for the patient at very high risk of fracture. Sequential therapy following once-weekly as well as daily teriparatide treatment is a potent option for those patients.
- Open Access
- 16 March 2024
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 10 (1) , 3-10
Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
- 16 March 2024
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 10 (1) , 3-10
Open AccessAsia-Pacific consensus on long-term and sequential therapy for osteoporosis
- Open Access
- 28 January 2023
- Published by Springer Nature in Calcified Tissue International
- Vol. 112 (4) , 430-439
Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
The positive link between osteoporosis and hypercholesterolemia has been documented, and bone resorption inhibitors, such as nitrogen-containing bisphosphonates (N-BP) and selective estrogen receptor modulators (SERMs), are known to reduce serum cholesterol levels. However, the relationship between the baseline cholesterol level and incident fracture rate under the treatment using the bone resorption inhibitors has not been documented. We investigated the relation between vertebral fracture incident and the baseline cholesterol levels and cholesterol-lowering effect of N-BP and SERM in osteoporosis through a prospective randomized open-label study design. Patients with osteoporosis (n = 3986) were allocated into two groups based on the drug used for treatment: minodronic acid (MIN) (n = 1624) as an N-BP and raloxifene (RLX) as an SERM (n = 1623). Serum levels of cholesterol and incidence of vertebral fracture were monitored for 2 years. The vertebral fracture rates between the two groups were compared using the pre-specified stratification factors. The patients receiving MIN with baseline low-density lipoprotein (LDL)-cholesterol level of ≥ 140 mg/dL, high-density lipoprotein cholesterol level < 40 mg/dL, age group of ≥ 75 years, and T score of BMD ≥ -3 SD had significantly lower vertebral fracture rates than those receiving RLX (incidence rate ratios (IRR) 0.45 [95% confidence interval (CI) 0.30 0.75, p = 0.001], 0.25 [95% CI 0.09 0.65, p = 0.005], 0.71 [95% CI 0.56 0.91, p = 0.006], 0.47 [95% CI 0.30 0.75, p = 0.0012], respectively). The cholesterol-lowering effect was stronger in the RLX group than in the MIN group, regardless of prior statin use. These results indicated that MIN treatment was more effective in reducing fracture risk in patients with higher LDL cholesterol levels, although its cholesterol-lowering ability was lesser than the RLX treatment.Trial registration University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR), No. UMIN000005433; date: April 13, 2011.
- 28 January 2023
- Published by Springer Nature in Calcified Tissue International
- Vol. 112 (4) , 430-439
Open AccessEffect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
The positive link between osteoporosis and hypercholesterolemia has been documented, and bone resorption inhibitors, such as nitrogen-containing bisphosphonates (N-BP) and selective estrogen receptor modulators (SERMs), are known to reduce serum cholesterol levels. However, the relationship between the baseline cholesterol level and incident fracture rate under the treatment using the bone resorption inhibitors has not been documented. We investigated the relation between vertebral fracture incident and the baseline cholesterol levels and cholesterol-lowering effect of N-BP and SERM in osteoporosis through a prospective randomized open-label study design. Patients with osteoporosis (n = 3986) were allocated into two groups based on the drug used for treatment: minodronic acid (MIN) (n = 1624) as an N-BP and raloxifene (RLX) as an SERM (n = 1623). Serum levels of cholesterol and incidence of vertebral fracture were monitored for 2 years. The vertebral fracture rates between the two groups were compared using the pre-specified stratification factors. The patients receiving MIN with baseline low-density lipoprotein (LDL)-cholesterol level of ≥ 140 mg/dL, high-density lipoprotein cholesterol level < 40 mg/dL, age group of ≥ 75 years, and T score of BMD ≥ -3 SD had significantly lower vertebral fracture rates than those receiving RLX (incidence rate ratios (IRR) 0.45 [95% confidence interval (CI) 0.30 0.75, p = 0.001], 0.25 [95% CI 0.09 0.65, p = 0.005], 0.71 [95% CI 0.56 0.91, p = 0.006], 0.47 [95% CI 0.30 0.75, p = 0.0012], respectively). The cholesterol-lowering effect was stronger in the RLX group than in the MIN group, regardless of prior statin use. These results indicated that MIN treatment was more effective in reducing fracture risk in patients with higher LDL cholesterol levels, although its cholesterol-lowering ability was lesser than the RLX treatment.Trial registration University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR), No. UMIN000005433; date: April 13, 2011.
- Open Access
- 14 October 2022
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (1) , 189-199
Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
Summary In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture. Purpose To determine whether the anti-fracture efficacy of sequential therapy with teriparatide, followed by alendronate is superior to that of monotherapy with alendronate, a prospective, randomized, open-label, blinded-endpoint trial was performed. Methods Japanese women aged at least 75 years were eligible for the study, if they had primary osteoporosis and if they were at high risk of fracture. Patients were randomly assigned (1:1) to receive the sequential therapy (once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks, followed by alendronate for 48 weeks) or monotherapy with alendronate for 120 weeks. The primary endpoint in the final analysis was the incidence of morphometric vertebral fracture during the 120-week follow-up period. Results Between October 2014 and June 2020, 505 patients in the sequential therapy group and 506 in the monotherapy group were enrolled. Of these, 489 and 496, respectively, were included in the main analysis. The incidence of morphometric vertebral fracture during the 120-week follow-up period in the sequential therapy group (64 per 627.5 person-years, annual incidence rate 0.1020) was significantly lower than that in the monotherapy group (126 per 844.2 person-years, annual incidence rate 0.1492), with a rate ratio of 0.69 (95% confidence interval 0.54 to 0.88, P < 0.01). After 72 weeks, no patient had a severe adverse event that was considered related to the study drug. Conclusion Once-weekly injection of teriparatide, followed by alendronate resulted in a significantly lower incidence of morphometric vertebral fracture than alendronate monotherapy in women with osteoporosis who were at high risk of fracture. Trial registration number, date of registration jRCTs031180235 and UMIN000015573, March 12, 2019
- 14 October 2022
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (1) , 189-199
Open AccessSequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
Summary In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture. Purpose To determine whether the anti-fracture efficacy of sequential therapy with teriparatide, followed by alendronate is superior to that of monotherapy with alendronate, a prospective, randomized, open-label, blinded-endpoint trial was performed. Methods Japanese women aged at least 75 years were eligible for the study, if they had primary osteoporosis and if they were at high risk of fracture. Patients were randomly assigned (1:1) to receive the sequential therapy (once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks, followed by alendronate for 48 weeks) or monotherapy with alendronate for 120 weeks. The primary endpoint in the final analysis was the incidence of morphometric vertebral fracture during the 120-week follow-up period. Results Between October 2014 and June 2020, 505 patients in the sequential therapy group and 506 in the monotherapy group were enrolled. Of these, 489 and 496, respectively, were included in the main analysis. The incidence of morphometric vertebral fracture during the 120-week follow-up period in the sequential therapy group (64 per 627.5 person-years, annual incidence rate 0.1020) was significantly lower than that in the monotherapy group (126 per 844.2 person-years, annual incidence rate 0.1492), with a rate ratio of 0.69 (95% confidence interval 0.54 to 0.88, P < 0.01). After 72 weeks, no patient had a severe adverse event that was considered related to the study drug. Conclusion Once-weekly injection of teriparatide, followed by alendronate resulted in a significantly lower incidence of morphometric vertebral fracture than alendronate monotherapy in women with osteoporosis who were at high risk of fracture. Trial registration number, date of registration jRCTs031180235 and UMIN000015573, March 12, 2019
- Open Access
- 31 August 2022
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 6 (10) , e10673
Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)
Associations between urinary pentosidine, one of the advanced glycation end products in collagen, and the risk of fracture in patients with severe osteoporosis are unknown. In this study, we investigated whether the urinary pentosidine level is associated with the incidence of morphometric vertebral fracture and nonvertebral fracture using data of a randomized, controlled trial, JOINT‐05. JOINT‐05 enrolled Japanese women aged 75 years or older with primary osteoporosis. Patients were randomly assigned (1:1) to receive sequential therapy (teriparatide followed by alendronate) or monotherapy with alendronate for 120 weeks. Incidences of vertebral and nonvertebral fractures were assessed morphologically. During treatment, urinary levels of pentosidine and serum levels of bone turnover markers (osteocalcin, procollagen type I amino‐terminal propeptide, and tartrate‐resistant acid phosphatase 5b) were measured. A total of 967 patients with baseline pentosidine levels were included in the study. Of these, 137 had vertebral fractures, and 42 had nonvertebral fractures. The rate ratios for vertebral fracture for the second (30–39 pmol/mL), third (40–49 pmol/mL), and fourth quartile (≥50 pmol/mL) groups divided by pentosidine level compared with the first quartile (p = 0.06), 1.51 (95% CI 0.87–2.61, p = 0.14), and 1.69 (95% CI 1.01–2.83, p = 0.05), respectively. The corresponding rate ratios for nonvertebral fracture were 3.07 (95% CI 0.88–10.70, p = 0.08), 2.34 (95% CI 0.61–8.95, p = 0.22), and 3.95 (95% CI 1.14–13.67, p = 0.03), respectively. The association of the urinary pentosidine level with the incidence of nonvertebral fracture was the strongest among the biomarkers assessed in the study. In conclusion, the urinary pentosidine level was associated with the risk of fracture in patients with severe osteoporosis receiving teriparatide or alendronate. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
- 31 August 2022
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 6 (10) , e10673
Open AccessAssociation of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)
Associations between urinary pentosidine, one of the advanced glycation end products in collagen, and the risk of fracture in patients with severe osteoporosis are unknown. In this study, we investigated whether the urinary pentosidine level is associated with the incidence of morphometric vertebral fracture and nonvertebral fracture using data of a randomized, controlled trial, JOINT‐05. JOINT‐05 enrolled Japanese women aged 75 years or older with primary osteoporosis. Patients were randomly assigned (1:1) to receive sequential therapy (teriparatide followed by alendronate) or monotherapy with alendronate for 120 weeks. Incidences of vertebral and nonvertebral fractures were assessed morphologically. During treatment, urinary levels of pentosidine and serum levels of bone turnover markers (osteocalcin, procollagen type I amino‐terminal propeptide, and tartrate‐resistant acid phosphatase 5b) were measured. A total of 967 patients with baseline pentosidine levels were included in the study. Of these, 137 had vertebral fractures, and 42 had nonvertebral fractures. The rate ratios for vertebral fracture for the second (30–39 pmol/mL), third (40–49 pmol/mL), and fourth quartile (≥50 pmol/mL) groups divided by pentosidine level compared with the first quartile (p = 0.06), 1.51 (95% CI 0.87–2.61, p = 0.14), and 1.69 (95% CI 1.01–2.83, p = 0.05), respectively. The corresponding rate ratios for nonvertebral fracture were 3.07 (95% CI 0.88–10.70, p = 0.08), 2.34 (95% CI 0.61–8.95, p = 0.22), and 3.95 (95% CI 1.14–13.67, p = 0.03), respectively. The association of the urinary pentosidine level with the incidence of nonvertebral fracture was the strongest among the biomarkers assessed in the study. In conclusion, the urinary pentosidine level was associated with the risk of fracture in patients with severe osteoporosis receiving teriparatide or alendronate. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
- 1 December 2021
- Published by Springer Nature
- p. 431-440
Effects of the Drug Treatment for Osteoporosis in Clinical Settings, Monotherapy or Concurrent Therapy
- 1 December 2021
- Published by Springer Nature
- p. 431-440
Effects of the Drug Treatment for Osteoporosis in Clinical Settings, Monotherapy or Concurrent Therapy
- 1 December 2021
- Published by Springer Nature
- p. 231-242
Fracture Healing and Non-Union
- 27 August 2021
- Published by Springer Nature in Osteoporosis International
- Vol. 32 (10) , 2143
Correction to: A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese osteoporosis intervention Trial-05
- 27 August 2021
- Published by Springer Nature in Osteoporosis International
- Vol. 32 (10) , 2143
Correction to: A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese osteoporosis intervention Trial-05